The long-anticipated legal battle over the contentious Covishield vaccine, developed by AstraZeneca and manufactured in India by the Serum Institute of India (SII), has finally reached the highest court of the land. A recent petition filed in the Supreme Court by advocate Vishal Tiwari has reignited the discourse on the vaccine’s safety, potential risks, and the need for a comprehensive investigation into its purported side effects.
At the heart of this legal quagmire lies the harrowing tale of Alex Mitchell, a key litigant in the UK proceedings against AstraZeneca. Mitchell recounted the horrific ordeal he endured, with numerous blood clots removed from his legs and lower abdomen – a scenario his doctors had never encountered before. His narrative is but one among many that have surfaced in the wake of the Covishield vaccination campaign, underscoring the gravity of the situation.
AstraZeneca’s recent admission that its vaccine could, albeit rarely, induce Thrombosis with Thrombocytopenia Syndrome (TTS) – a condition characterised by abnormally low platelet levels and blood clot formation – has added fuel to the fire. With this acknowledgment, the Serum Institute of India, as a licensee of AstraZeneca’s vaccine formula, finds itself embroiled in potential legal ramifications.
The tragic case of Karunya, a young woman who lost her life ten days after receiving the Covishield vaccine in 2021, has further galvanised her bereaved father, Venugopalan Govindan, to contemplate legal action against both SII and AstraZeneca. Govindan’s profound dissatisfaction with AstraZeneca’s belated admission and SII’s failure to suspend vaccine distribution following reports of blood clot-related fatalities in March 2021 has resonated across social media platforms.
The petition filed by Tiwari seeks the constitution of an expert medical panel, headed by an AIIMS expert and supervised by a retired Supreme Court judge, to study the risk factors associated with the Covishield vaccine. Additionally, the plea calls for the establishment of a ‘Vaccine Damage Payment System’ to support citizens or families who have suffered debilitating health setbacks or even deaths after receiving the vaccine.
While the government has formed a national committee to probe such occurrences, the determination of insufficient evidence linking Karunya’s demise to the vaccine underscores the intricate challenge of establishing causality in rare adverse events. However, the narratives shared by individuals like Govindan underscore the exigency for robust surveillance, reporting mechanisms, and support infrastructure to address post-vaccination complications comprehensively.
The Covishield controversy has also drawn criticism from various quarters, with the Indian Youth Congress questioning the government’s silence and alleging potential conflicts of interest involving electoral bonds received from the Serum Institute. Doctors and medical experts have weighed in, acknowledging the rarity of TTS but emphasising the need for informed consent, thorough monitoring, and transparent reporting of adverse events.
A Global Covid Vaccine Safety Project study conducted an extensive analysis of adverse events associated with Covid-19 vaccines across multiple regions, confirming previously identified rare safety signals, including elevated risks of Guillain-Barré syndrome, cerebral venous sinus thrombosis, and acute disseminated encephalomyelitis following certain vaccine doses. The study also highlighted differences in adverse event reporting rates between countries, potentially influenced by the robustness of reporting systems and physiological factors.
As the legal battle unfolds, SII’s competitor, Bharat Biotech, has underscored the efficacy of its homegrown Covaxin vaccine, claiming it was meticulously evaluated and underwent trials within India. However, the overarching concern remains the potential risks associated with Covishield and the need for transparency, accountability, and a comprehensive support system for those affected.
The Covishield controversy has brought to the forefront the delicate balance between rapid vaccine development, public health interests, and the ethical imperative of ensuring informed consent and rigorous safety protocols. As the Supreme Court grapples with this complex issue, the nation watches with bated breath, hoping for a resolution that upholds the principles of justice, transparency, and the sanctity of human life.
(The writer can be reached at dipakkurmiglpltd@gmail.com)
